Manufacturer of Controlled Substances, Notice of Registration; Johnson Matthey, Inc., 16298 [2013-05803]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with NOTICES
16298
Federal Register / Vol. 78, No. 50 / Thursday, March 14, 2013 / Notices
Section 404(d) directs the
Commission to conduct an annual
review of the program for the purpose
of evaluating the effectiveness of the
program and making recommendations
for improvements. The Commission is
required to submit its reports containing
the results of its reviews to the House
Committee on Ways and Means and the
Senate Committee on Finance. The
Commission submitted its report on its
first annual review (USITC Publication
4175) on July 28, 2010, its report on its
second annual review (USITC
Publication 4246) on July 22, 2011, and
its report on the third annual review
(USITC Publication 4175) on July 26,
2012: The Commission expects to
submit its report on its fourth annual
review by July 26, 2013.
The Commission instituted this
investigation pursuant to section 332(g)
of the Tariff Act of 1930 to facilitate
docketing of submissions and also to
facilitate public access to Commission
records through the Commission’s EDIS
electronic records system.
Submissions: Interested parties are
invited to file written submissions
concerning this fourth annual review.
All written submissions should be
addressed to the Secretary and must
conform to the provisions of section
201.8 of the Commission’s Rules of
Practice and Procedure (19 CFR 201.8).
All written submissions must conform
with the provisions of section 201.8 of
the Commission’s Rules of Practice and
Procedure (19 CFR 201.8). Section 201.8
and the Commission’s Handbook on
Filing Procedures require that interested
parties file documents electronically on
or before the filing deadline and submit
eight (8) true paper copies by 12:00 p.m.
eastern time on the next business day.
In the event that confidential treatment
of a document is requested, interested
parties must file, at the same time as the
eight paper copies, at least four (4)
additional true paper copies in which
the confidential information must be
deleted (see the following paragraph for
further information regarding
confidential business information).
Persons with questions regarding
electronic filing should contact the
Secretary (202–205–2000).
Any submissions that contain
confidential business information must
also conform to the requirements of
section 201.6 of the Commission’s Rules
of Practice and Procedure (19 CFR
201.6). Section 201.6 of the rules
requires that the cover of the document
and the individual pages be clearly
marked as to whether they are the
‘‘confidential’’ or ‘‘non-confidential’’
version, and that the confidential
business information is clearly
VerDate Mar<15>2010
16:51 Mar 13, 2013
Jkt 229001
identified by means of brackets. All
written submissions, except for
confidential business information, will
be made available for inspection by
interested parties.
The Commission intends to publish
only a public report in this review.
Consequently, the report that the
Commission sends to the committees
will not contain any confidential
business information. Any confidential
business information received by the
Commission in this investigation and
used in preparing its report will not be
published in a manner that would
reveal the operations of the firm
supplying the information.
Issued: March 8, 2013.
By order of the Commission.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–05830 Filed 3–13–13; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Registration;
Johnson Matthey, Inc.
By Notice dated November 5, 2012,
and published in the Federal Register
on November 13, 2012, 77 FR 67676,
Johnson Matthey, Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Propiram (9649) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: February 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–05803 Filed 3–13–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Comment Request for Information
Collection: Confidentiality and
Disclosure of State Unemployment
Compensation Information Final Rule
and State Income and Eligibility
Verification Provisions of the Deficit
Reduction Act of 1984, Extension
Without Change
Employment and Training
Administration (ETA), Labor.
ACTION: Notice.
AGENCY:
The Department of Labor, as
part of its continuing effort to reduce
paperwork and respondent burden
conducts a preclearance consultation
program to provide the general public
and federal agencies with an
opportunity to comment on proposed
SUMMARY:
E:\FR\FM\14MRN1.SGM
14MRN1
]]>Agencies
[Federal Register Volume 78, Number 50 (Thursday, March 14, 2013)]
[Notices]
[Page 16298]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-05803]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances, Notice of Registration;
Johnson Matthey, Inc.
By Notice dated November 5, 2012, and published in the Federal
Register on November 13, 2012, 77 FR 67676, Johnson Matthey, Inc.,
Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New
Jersey 08066-1742, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)........... I
Tetrahydrocannabinols (7370)............... I
Dihydromorphine (9145)..................... I
Difenoxin (9168)........................... I
Propiram (9649)............................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Nabilone (7379)............................ II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Diphenoxylate (9170)....................... II
Ecgonine (9180)............................ II
Hydrocodone (9193)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Johnson Matthey, Inc., to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Johnson Matthey, Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: February 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-05803 Filed 3-13-13; 8:45 am]
BILLING CODE 4410-09-P
